[Gut] Researchers aimed to develop mouse models of sporadic and hereditary DGC by inactivation of Cdh1 in the mouse stomach. They generated tamoxifen-inducible Cre/loxP mouse models of DGC driven by the Cd44 promoter with a tdTomato reporter.

[Cell Reports] Scientists employed mouse genetics to reveal that Hippo signaling regulates stomach epithelial development by balancing epithelial proliferation and differentiation.

[Biology Direct] Researchers identified mixed lineage kinase domain-like protein (MLKL) as a key regulator of ferroptosis resistance in colorectal cancer, promoting tumor cell survival by coordinating antioxidant defenses and ESCRT-III–mediated membrane repair.

[International Immunopharmacology] Investigators identified ecto-nicotinamide adenine dinucleotide oxidase 1 (ENOX1) as a driver of gastric cancer progression, promoting epithelial–mesenchymal transition and M2 macrophage polarization through Snail2 signaling.

[Bioorganic Chemistry] Scientists developed AspMet, a dual MET/COX-2 inhibitor that suppresses gastric and colorectal cancer growth by blocking oncogenic signaling, epithelial–mesenchymal transition, and angiogenesis.

[Biochemical and Biophysical Research Communications] Researchers showed that lactate-driven S100A8 lactylation stabilizes the protein by blocking RNF5-mediated degradation, promoting colorectal cancer progression.

[International Journal of Oncology] The authors summarize the molecular drivers of glycolytic reprogramming in gastric cancer, the mechanisms by which lactate‑centered crosstalk reshapes stromal and immune compartments, and emerging therapeutic strategies.

[LTZ Therapeutics] LTZ Therapeutics announced that the US FDA has cleared its Investigational New Drug (IND) application to evaluate LTZ-232 to treat patients with advanced metastatic colorectal cancer and other solid tumors.

[Karolinska Institutet] A prostate cancer research initiative in Sweden has been made possible by a donation from Björn Gysell. The investment will enable Karolinska Institutet’s research environment in prostate cancer to develop the next generation diagnostics and therapies using AI, genomics and precision medicine.

[Oncogene] Scientists identified SET domain bifurcated 1 (SETDB1) as a key regulator of epithelial–mesenchymal transition (EMT) and metastasis through direct repression of RhoB, the small GTPase. SETDB1 is genomically amplified and transcriptionally upregulated in metastatic CRPC.

[British Journal of Cancer] Researchers assessed poly (ADP‒ribose) polymerase (PARP) inhibitors alone and with androgen receptor pathway inhibitors in prostate cancer cell lines, metastatic patient-derived organoids, and LN-metastatic tissue slice cultures.

[NeoGenomics, Inc.] NeoGenomics, Inc. announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the US FDA for patients with prostate adenocarcinoma.